About Us

We are among the fastest-growing pharmaceutical companies in the Indian Pharmaceutical Market, holding brand leadership across several super-specialties including Rheumatology, Pulmonology, Cardiology, Endocrinology, Urology, Gastroenterology, Psychiatry, Neurology, Oncology, Hematology, Internal Medicine, Gynaecology, and Pain Management.

Driven by our core belief that every life matters and that everyone deserves access to quality medicines, our vision is anchored in efficacy, affordability, and accessibility. This commitment to improving lives inspires our pursuit of continuous innovation, enabling us to touch and impact human lives more meaningfully, today and tomorrow.

Aligned with the national vision of Atmanirbhar Bharat, we are addressing critical therapy gaps in India through several first-time-in-India launches across key therapeutic areas. We have emerged as category leaders in treating pulmonary arterial hypertension, heart failure, diabetes, benign prostatic hyperplasia (BPH), overactive bladder, irritable bowel syndrome (IBS), ulcerative colitis, anemia, endometriosis, and various cancers and orphan diseases. Our leadership also spans anti-platelet, anticoagulant, anti-diabetic, anti-ulcerant, anti-depressant, anti-epileptic, and pain management therapies.

Backed by a pan-India presence and a dedicated field force of 2,000+ professionals, we actively engage with over 1 lakh leading medical practitioners and healthcare institutions nationwide. With a robust portfolio of bio-equivalent, innovative, and affordable medicines, we continue to earn the trust of millions of patients—delivering impactful solutions for India’s diverse healthcare needs.

MSN Journey

MSN Incorporation to API

Dr. MSN Reddy founded MSN Laboratories to produce high-quality pharmaceutical ingredients (APIs) in support of our partners.

1st DMF Filing

This milestone marks the beginning of our longstanding commitment to regulatory excellence, and our commitment to deliver quality products.

Established Formulations and First export

Dr. MSN Reddy launched our formulations division, enhancing our ability to deliver high-quality care to patients. This year also marked a key milestone with our first export, marking the start of our impact on global healthcare.

Established Asia’s Biggest R&D Center

MSN established Asia’s largest integrated R&D center, bringing formulation and API research together under one roof. A milestone that continues to power our purpose “Research for Better Medicine”

Established First Export Oriented Unit

This key step expanded our international reach, boosting our production and distribution capabilities to serve patients around the world.

Establishment of Vivanta generics as MSN’s subsidiary

Vivanta Generics, located in the UK, has significantly contributed to enhancing our capabilities in the generics market.

Establishment of first international manufacturing plant - New Jersey, USA

The manufacturing facility in New Jersey, USA, accelerated our ability to serve customers globally and expanded our production capacity.

No 1 in Active DMF filings in the world

Showcasing how far we have come since 2006, this accomplishment meant a great deal to all the people who have contributed to our commendable record in regulatory compliance.

Expanding to Injectables & Ophthalmics

This expansion to our portfolio increased our capacity to help patients in a variety of medical circumstances.

Launch of Biotech

This new division is dedicated to advancing research and development in biotechnology, focusing on creating cutting-edge therapies and solutions to address complex medical needs

The Path to Sustainability

Sustainability lies at the heart of how we operate and grow. We actively reduce waste, recycle responsibly, and invest in green technologies that enhance energy efficiency and lower emissions. Beyond environmental stewardship, we champion diversity, equity, and inclusion, as we build a workplace where every individual is valued and empowered to thrive. Our ESG initiatives reflect a long-term commitment to responsible growth and a healthier planet.